💉 NASDAQ: STSS - Breaking News!

ALERT! NASDAQ: STSS Before I tell you all about this company, you need to see the News they just announced this morning! BREAKING NEWS Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023 High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond Company to launch next generation specialty polymer-based syringe products for the healthcare market NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces the advancement of the Company's specialized prefillable syringe ("PFS") system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina. Braden Miller, Sharps Director of Product Management, commented, “Sharps has developed an alternative high-quality solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution compared to traditional glass syringe systems. These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which can eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors. The ability to produce these innovative products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance and safety when compared to similar glass syringe products. We look forward to introducing this line of next generation products to the market." Sharps' specialized product pipeline and market strategy will include a broad range of sizes, silicon free systems that address contamination issues for the broader healthcare market, dual chamber systems that improve drug shelf life while reducing unnecessary packaging, and customized solutions for systems that serve the growing autoinjector segment. Sharps announced a manufacturing and [research partnership]( with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina. Initial demand will be supported by manufacturing capacity of 20+ million units, with additional capacities that can be scaled by 2025 with an additional 100 million units annually. Products will be manufactured utilizing state-of-the-art Injection molding technologies with highly automated assembly lines. The products will be sterilized using an ecofriendly clean sterilization option easily adaptable for the pharmaceutical market. Sharps' PFS systems will utilize ISO Standard Nest and Tubs that will be compatible with existing fill-finish technologies to provide a drop-in solution for the industry. Robert Hayes, Sharps Chief Executive Officer, commented: "Following years of research and development, Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology. The opportunity to advance our product and manufacturing strategy to include high value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond. The launch of these products could not come at a better time to support a market that is in demand for products produced in the USA that provide specialized solutions for customers that need optionality for their drug filling operations. We look forward to providing updates as we commence manufacturing in South Carolina and introduce our new products to the market." Growing Transition from the Use of Old Bulk Syringes to New Innovative Prefillable Syringes: Over the last 20 years, the pharmaceutical syringe operational model has shifted from the use of bulk syringes to prefillable syringes, increasing prefillables from 15% to 85%. By purchasing the prewashed and sterile systems in specialty nest and tub packaging, pharmaceutical operations can decrease their manufacturing footprint by about 50%. With new technologies in fill-finish equipment, syringe filling has become more accurate and faster in this smaller footprint. This is the reason why prefillable syringe systems are considered a high growth segment of the drug packaging market. There has been a rapid increase in demand for these systems and with legacy drugs and including the COVID 19 vaccine moving into the more economical packaging of PFS. Lead times for the procurement of PFS systems continue to rise with pharmaceutical companies expected average lead times increasing to 12-24 months from their current suppliers. The most common PFS systems are designed with pharmaceutical glass barrels which require the use of a complex series of production, washing and preparation processes prior to sterilization. A diminishing workforce of the highly skilled operators needed to manufacture glass syringes only adds speculation to the growing lead times for customers. Even with significant advancements in statistical modeling for production, the glass forming world is still struggling to implement these key manufacturing principles today. Sharps Technology's solutions will support the future demand of specialty polymer-based syringe drug filling solutions, and its products should address the demand in the growing market for them. Press Release: There’s a good reason why Insiders are loading up on this emerging healthcare company… Greetings All, The modern world received a major wake-up call because of the pandemic. The essence of progress in healthcare has become one of the biggest bright sides these last few years. The pandemic has had a substantial impact on immunization and vaccination activities. Many people have no idea that most syringes waste significant amounts of injectable medicine which are thrown away with the used needle/syringe. This adds to cost and reduces the amount of life-saving injectable drugs which are available to us all. Whether a pandemic, hard-to-manufacture drugs, or long-term chronic illness, we can't afford to waste this precious supply. This brings attention to a little-known company on the NASDAQ called Sharps Technology Inc. which is offering the world better drug delivery technology. Sharps Technology Inc. (NASDAQ: STSS) is trading under $2, has had tremendous insider purchases, and boasts many BULLISH ratings on several investment sites. The stock also has a relatively tiny trading float at just [5.6M shares]( making for a limited amount of shares available. What’s most exciting about STSS right now is the fact that the company has transitioned from a pre-revenue research & development start-up to a REVENUE GENERATING manufacturing company. Shipments were anticipated to begin at the end of last year, supported by STSS’s announced distribution and sales agreement with Nephron Pharmaceuticals (a leader in pre-filled sterile syringes) and its European customers. “This is a transformative point for our company as we move from a pre-revenue research & development start-up to a true manufacturing company that should generate revenue in the first half of 2023.” “The recently signed distribution agreement with Nephron Pharmaceuticals accelerates the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary. The ability to pull forward our sales plan for customers in the US will create a unique opportunity for early revenue at Sharps. We expect to have our first products available for sale in the US by the end of January 2023, with additional products to be added to the distribution network by mid-year of 2023." - Robert Hayes, Sharps Technology CEO 2023 could be a monumental year for the company and shareholder growth! With product commercialization and expanded manufacturing capacity Sharps Technology, Inc. (NASDAQ: STSS) will be able to support the industry with innovative, market-leading drug delivery solutions, all while generating potentially significant revenues. Make sure the company is on your radar! [pastedGraphic.png] Sharps Technology, Inc. (NASDAQ: STSS) is an innovative medical device and drug delivery company offering patented, best-in-class syringe products. BULLISH RATINGS Currently STSS has a STRONG BUY rating at Investing.com as seen below: [pastedGraphic_1.png] STSS additionally has an overall “BULLISH” rating at Stockta.com as seen [HERE]( and a “STAY LONG” rating at AmericanBulls.com as seen [HERE.]( The Problem The use of standard syringes that are not designated as low waste or ultra-low waste products typically creates a dead space area within the syringe where excess medication is trapped and cannot be used. This dead space then causes the healthcare provider to throw away the unused medication. The trapped medication in the dead space of a standard syringe can waste as much as 100 microliters (uL) of medication or more! The Pharmaceutical companies that fill their medication into vials understand this and must then overfill the vial with drug therapy to compensate for the problem. As the costs for medication and medical treatments rise, the discarded medication can cost the industry millions of dollars, or more, globally. The Solution STSS’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US. When healthcare providers use ultra-low waste syringes with multi-dose vials, it allows for the availability of up to 20% to 40% more medication for patients that need the treatment. This medication availability is created by using more efficient syringes designated as low-waste and ultra-low waste products, and not trapping medication within the syringe after the dose is given. Highlights - New legislation coming into effect will impact the pharmaceutical industry and likely escalate the need for low-waste space and ultra-low-waste space drug delivery devices. - The company is meeting the strong and growing demand for smart safety syringes. - STSS acquired Safegard Medical, an FDA/CE-approved syringe manufacturer in the EU. Along with pre-fillable syringes, it plans to deliver 100 million units over the next 24 months. - STSS is confident in its operations and multiple insiders are buying shares. In the last twelve months, the biggest single purchase by an insider was when Independent Non-Executive Director Timothy Ruemler bought US$140k worth of shares at a price of US$1.25 per share. This purchase was made at a higher amount than the current share price, which may indicate some serious optimism about STSS’s future. - Both the safety syringe market and the pre-fillable syringe market are expected to grow rapidly between 2022 and 2028. This sharp growth is led by the increase in Covid inoculations, the overall growth in the population, new injectable medications coming through the regulatory process and the growing instance of chronic diseases. The Safety Syringe market is expected to grow at a CAGR of 9.6% from 2021-2027 to exceed [US$ 14.4 billion by 2027.]( - Each year almost [20 billion injections]( are administered, globally. WHO are advocating for the use of low waste space syringes, passive safety devices which engage automatically and auto-disable features. - STSS’s commercialization and growth strategies also include joint presentations with their pharmaceutical partner, to service the pharmaceutical industry with specialty drug delivery products produced in the US. European Facility STSS’s purchase of the European facility in Hungary was finalized in the summer of 2022 and the company has invested in infrastructure and equipment upgrades to prepare the plant for a full manufacturing schedule. Syringe products produced by Sharps comply with all applicable FDA and ISO requirements and have been awarded the European Union’s CE Mark. The Sharps Hungary team, led by General Manager Filippo Filippi, brings together a dedicated and knowledgeable manufacturing force, with more than 20 years of experience in supplying the world with high quality, innovative syringe products. Prior to the GM position, Filippi’s career spanned years of building, managing, and supporting multiple manufacturing sites across Europe, Asia, and Africa. The Hungary plant is vertically integrated in that it has the capability to manufacture the syringe components by injection molding, assemble the devices on automated lines or by manual assembly if required, and to sterilize the products on-site through the Ethylene Oxide (EtO) sterilization process. This last stage of the syringe manufacturing process is unique in the industry and gives Sharps an advantage in supporting shortened lead times as compared to the common need to utilize a third-party for sterilization. The plant has manufacturing capacity to supply more than 50 million units today and the facility could be expanded to produce 250 million units or more over the next couple of years. Pre-filled Syringes Market Pre-filled syringes have emerged as one of the fastest-growing choices for unit-dose medication as the pharmaceutical industry seeks new and more convenient drug delivery methods. With PFS/RTF syringes, pharmaceutical companies are able to minimize drug waste and increase product life span, while patients are able to self-administer injectable drugs at their home instead of the hospital. Ready-To-Use - Pre-Filled Syringes: - Types: Plastic and Type I B/S Glass - Applications: Vaccines, Diabetes, Complex High Value Therapies (Gene-Therapy) - End Users: Branded Pharma, CMOs and Biologics - Target Markets: North America Growing demand for efficient and easy-to-use drug delivery devices and increasing efforts of healthcare professionals to reduce hospital errors are the principal factors driving the market growth. The Vaccines Market The [global vaccines market]( is projected to grow from $61.04 billion in 2021 to $125.49 billion in 2028 at a CAGR of 10.8% in the forecast period, 2021-2028. Vaccines are the most powerful and cost-effective way to protect billions of people in the world. According to the [WHO]( immunization awareness and government initiatives have helped prevent 2-3 million deaths a year. Great investments along with merging and partnerships of companies are boosting the production and sales of products globally. The Covid-19 outbreak had led to a shutdown of manufacturing syringes which in turn led to a supply shortage at a global scale. The rise in the need for vaccinations and immunizations, plus a surge in the geriatric population, an increase in the number of surgical procedures, as well as a rise in chronic diseases have contributed to a demand for syringes. Specialty Syringes - Vial Application - Global Smart Syringe Market @ $14 billion USD by 2026 w10.0%+ CAGR - Types: Auto-Disable Syringes and Safety Syringes - Applications: Vaccination and Drug Delivery - End Users: Hospitals, HMOs and Clinics - Target Markets: North America, Europe and ROW - Sharps Technology listed as a supplier Source: © Infinium Global Research The PFS/RTF syringe product segment especially will be a priority for the company created through its collaboration with Nephron. This product segment is expected to be significant in revenue and profitability goals! In summary… Sharps Technology, Inc. (NASDAQ: STSS) is the newest player in the drug delivery device market to go public (last year!) and could see tremendous blue-sky growth in its future as it continues to ramp up its commercialization efforts. With the global shortage of syringes that comply with the World Health Organization (WHO) requirements, there is a strategic opportunity for STSS to take market share and support the healthcare industry with a better drug delivery platform. The combination of features and benefits for the Sharps products will save lives and eliminate the waste of critically needed medical treatments and therapies for the industry! STSS anticipates shipping first orders of vial draw product by the beginning of 2023 and ready to fill product in mid-2023 to create initial revenue in 2023 and profits in early 2024, The fact that multiple insiders have loaded up sends a positive message that they believe in the company’s value. BULLISH ratings are piling up, and with a tiny trading float, STSS is one to keep a very close eye on! The company could be one of the most exciting growth stories on Wall Street in 2023! Start your research now! Copyright 2022 © PTE.la is owned and operated by the owner of CareBear Marketing Group LLC and IR Agency LLC. [Disclaimer and Privacy]( more Information please contact Support@pte.la This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. CareBear Marketing Group and/or IR Agency LLC, its managers, its employees, affiliates and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses. You received this message as part of your subscription to PTE. PTE is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by the owner of CareBear Marketing Group and IR Agency LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “PTE” refers to CareBear Marketing Group and/or IR Agency LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and the number of shares here. We do not own any shares in STSS, because we do have a relationship with a company (Tradigital Marketing Group) that does own shares please see their disclaimer here: . We have been compensated up to Four-Hundred Thousand Dollars Cash ($400,000) via credit card processing for lead generation, content distribution and other digital marketing efforts from a third-party Open Market Media Inc for a 2 Month Marketing Program regarding STSS with a start date of 11/28/2022 to 01/28/2023. PTE’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, PTE often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](